1517 related articles for article (PubMed ID: 15531005)
1. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
2. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
3. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
Hung YJ; Chen YC; Pei D; Kuo SW; Hsieh CH; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
5. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
6. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
Cuellar GE; Ruiz AM; Monsalve MC; Berber A
Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
[TBL] [Abstract][Full Text] [Related]
7. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
[TBL] [Abstract][Full Text] [Related]
8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
9. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
10. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
11. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
12. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chou KM; Huang BY; Fanchiang JK; Chen CH
Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
Kaukua JK; Pekkarinen TA; Rissanen AM
Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
17. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
18. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
19. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
Toubro S; Hansen DL; Hilsted JC; Porsborg PA; Astrup AV;
Ugeskr Laeger; 2001 May; 163(21):2935-40. PubMed ID: 11402974
[TBL] [Abstract][Full Text] [Related]
20. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
